# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wedbush analyst Laura Chico initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Outperform rating and announces Pri...
The Dow Jones index closed higher by over 400 points on Wednesday. When insiders purchase or sell shares, it indicates their co...
Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.220) per share which missed the analyst consensus estimate of ...
https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20240009160
BTIG analyst Thomas Shrader initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Buy rating and announces Price Targ...
-SEC Filing
- SEC Filing